Characterization of host immunity to cytomegalovirus pp150 (UL32)

Corinna La Rosa1, Zhongde Wang, Simon F Lacey

  • 1Laboratory of Vaccine Research, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Human Immunology
|February 8, 2005
PubMed

Insights

Researchers identified key viral protein fragments (minimal cytotoxic epitopes) from human cytomegalovirus (CMV) pp150 protein. These findings are crucial for developing effective CMV vaccines and immunotherapies targeting T-cell responses.

Area of Science:

  • Virology
  • Immunology
  • Vaccine Development

Background:

  • Human cytomegalovirus (CMV) phosphoprotein 150 (pp150) is a major viral tegument component.
  • pp150 is recognized by cytotoxic T lymphocytes (CTLs) restricted by human leukocyte antigen (HLA).
  • Identifying minimal cytotoxic epitopes (MCEs) of pp150 is vital for designing CMV peptide-based vaccines and immunotherapies.

Purpose of the Study:

  • To identify minimal cytotoxic epitopes (MCEs) within the CMV pp150 protein.
  • To evaluate the potential of these MCEs for developing CMV vaccines and immunotherapies.

Main Methods:

  • Generation of pp150-specific CTL clones from CMV-positive donors.
  • Infection of autologous fibroblasts with CMV or recombinant vaccinia virus expressing pp150.
  • Fine mapping of MCEs using T-cell epitope prediction algorithms and overlapping peptide screening.
  • In vitro stimulation assays with recombinant modified vaccinia Ankara virus expressing pp150.

Main Results:

  • Identified pp150(792-802) as an MCE for HLA A*6801-restricted CTLs.
  • Identified pp150(945-955) as an MCE for HLA A*0301-restricted CTLs.
  • In vitro stimulation induced high frequencies of CMV-specific CTLs and interferon-gamma production against the identified MCEs.

Conclusions:

  • The identified pp150 MCEs are targets of antiviral CTL responses in CMV-exposed individuals.
  • pp150 is a significant antigen for shaping cellular immune responses against CMV.
  • pp150-derived epitopes hold promise as key components for prophylactic and therapeutic CMV vaccines.